Eledon Pharmaceuticals (ELDN) Net Income towards Common Stockholders (2013 - 2026)

Eledon Pharmaceuticals (ELDN) has 14 years of Net Income towards Common Stockholders data on file, last reported at -$21.3 million in Q1 2026.

• Quarterly Net Income towards Common Stockholders fell 254.68% year-over-year to -$21.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$66.8 million (down 41.01% YoY) and the FY2025 annual result came in at -$42.3 million, down 32.31% from the prior year.
• Net Income towards Common Stockholders eased to -$21.3 million in Q1 2026, from -$19.9 million in the prior quarter.
• In the past five years, Net Income towards Common Stockholders ranged from a high of $6.7 million in Q3 2024 to a low of -$58.4 million in Q4 2022.
• A 5-year average of -$16.6 million and a median of -$11.4 million in 2023 frame the typical range for Net Income towards Common Stockholders.
• Annual changes were most pronounced in 2022 — Net Income towards Common Stockholders slumped 563.0% — and 2024, when it jumped 157.05%.
• Tracing ELDN's Net Income towards Common Stockholders over 5 years: stood at -$58.4 million in 2022, then surged by 82.12% to -$10.4 million in 2023, then plunged by 214.69% to -$32.8 million in 2024, then surged by 39.52% to -$19.9 million in 2025, then dropped by 7.13% to -$21.3 million in 2026.
• The last three Net Income towards Common Stockholders figures came in at -$21.3 million (Q1 2026), -$19.9 million (Q3 2025), and -$25.6 million (Q2 2025), per Business Quant data.